Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Oct 31;10(11):868-80.
doi: 10.1038/nrd3531.

Rapamycin passes the torch: a new generation of mTOR inhibitors

Affiliations
Review

Rapamycin passes the torch: a new generation of mTOR inhibitors

Don Benjamin et al. Nat Rev Drug Discov. .

Abstract

Mammalian target of rapamycin (mTOR) is an atypical protein kinase that controls growth and metabolism in response to nutrients, growth factors and cellular energy levels, and it is frequently dysregulated in cancer and metabolic disorders. Rapamycin is an allosteric inhibitor of mTOR, and was approved as an immuno-suppressant in 1999. In recent years, interest has focused on its potential as an anticancer drug. However, the performance of rapamycin and its analogues (rapalogues) has been undistinguished despite isolated successes in subsets of cancer, suggesting that the full therapeutic potential of targeting mTOR has yet to be exploited. A new generation of ATP-competitive inhibitors that directly target the mTOR catalytic site display potent and comprehensive mTOR inhibition and are in early clinical trials.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Diabetes. 2011 Mar;60(3):827-37 - PubMed
    1. Cancer Res. 2010 Jan 15;70(2):621-31 - PubMed
    1. Expert Opin Investig Drugs. 2008 Dec;17(12):1947-54 - PubMed
    1. Science. 2005 Nov 18;310(5751):1193-6 - PubMed
    1. Genes Dev. 2009 Aug 15;23(16):1929-43 - PubMed

Publication types

MeSH terms

LinkOut - more resources